title: Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.
abstract: Schizophrenia and other psychotic disorders are associated with increased risk of developing type 2 diabetes. However, previous studies are mainly based on clinical samples where the comorbidity may be stronger. We investigated in a general population survey the prevalence of type 2 diabetes in persons with psychotic disorders and in users of antipsychotic medication. The study was based on a nationally representative two-stage cluster sample of 8,028 persons aged 30 or over from Finland. Diagnostic assessment of psychotic disorders combined SCID-I interview and case note data. Prevalences of type 2 diabetes, adjusting for age and sex, were estimated by calculating predicted marginals. The prevalence estimate of type 2 diabetes was 22.0% among subjects with schizophrenia, 13.4% among subjects with other nonaffective psychosis and 6.1% in subjects without psychotic disorders. Only two subjects (3.4%) with affective psychosis had type 2 diabetes. Users of all types of antipsychotic medication had increased prevalence of type 2 diabetes. Our results suggest that type 2 diabetes is a major health concern among persons with schizophrenia and other nonaffective psychotic disorders and also in users of antipsychotic medication, but persons with affective psychosis in the general population may not have increased prevalence of type 2 diabetes.
authors.affiliation: Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. jaana.suvisaari@ktl.fi
authors.forename: Jaana
authors.initials: J
authors.lastname: Suvisaari
authors.forename: Jonna
authors.initials: J
authors.lastname: Perälä
authors.forename: Samuli I
authors.initials: SI
authors.lastname: Saarni
authors.forename: Tommi
authors.initials: T
authors.lastname: Härkänen
authors.forename: Sami
authors.initials: S
authors.lastname: Pirkola
authors.forename: Matti
authors.initials: M
authors.lastname: Joukamaa
authors.forename: Seppo
authors.initials: S
authors.lastname: Koskinen
authors.forename: Jouko
authors.initials: J
authors.lastname: Lönnqvist
authors.forename: Antti
authors.initials: A
authors.lastname: Reunanen
mesh_terms: D017677:Age Distribution; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D016009:Chi-Square Distribution; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D005260:Female; D005387:Finland / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D015995:Prevalence; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007328:Insulin